Article Text

Download PDFPDF
Randomised controlled trial
Evening dosing of antihypertensive medications results in better blood pressure control and decreases cardiovascular morbidity and mortality in patients with Type 2 diabetes
  1. Rajesh Mohandas,
  2. A Ahsan Ejaz
  1. Division of Nephrology, Hypertension and Transplantation, University of Florida, Gainesville, Florida, USA
  1. Correspondence to Rajesh Mohandas
    University of Florida, PO Box 100224, 1600 SW Archer road, Gainesville, FL 32610, USA; rajesh.mohandas{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlAbstract/FREE Full Text


Although Systolic Hypertension in Europe1 and Heart Outcomes Prevention Evaluation2 studies suggested nightly dosing of antihypertensive medications might lead to better cardiovascular outcomes, the Ambulatory Blood Pressure Monitoring for Prediction of Cardiovascular trial (ABPM),3 or Monitorización Ambulatoria para Predicción de Eventos Cardiovasculares (MAPEC), was the first study to include a comparison group randomised to morning only therapy. MAPEC showed improved blood pressure (BP) control, increased prevalence of normal sleep time blood pressure decline (ie, dipping) and reduced cardiovascular morbidity and mortality with nighttime chronotherapy. Since people with diabetes are prone to nocturnal …

View Full Text


  • Competing interests None.